Haematinics
[Haematinics ]
EPTIS Ringversuch Nr. 1615895 | Letze Änderung 2026-09-24 | URL: https://www.eptis.bam.de/pts1615895 https://www.eptis.bam.de/pts1615895
| Name des Anbieters | ||||||||||||||||||||||||||||
| Name des Anbieters | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||||||||
| Sprache(n) | English | |||||||||||||||||||||||||||
| Anmerkungen | Provides EQA coverage by means of predominantly endogenous levels of mainstream haematinic analytes which are required for the formation of blood cells in the process of hematopoiesis. The Scheme does cover the analytical working range, but does focus on the clinically important decision points. This Scheme includes Red Cell Folate. See separate schemes for Active B12/Holotranscobalamin and Erythropoietin. | |||||||||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | Clinical Chemistry Public & Private Labs | |||||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043:2023 | |||||||||||||||||||||||||||
| Weitere Ziele | Post market surveillance of testing methods | |||||||||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043:2023 |
|||||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||||||||
| Teilnahmegebühr | Contact provider for current fee, which depends on location and extent of service required. | |||||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Monthly (11 per year)) | |||||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2005 | |||||||||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Telefon: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Telefon: +44 121 414 7300 Fax: E-Mail: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
|||||||||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.